Shares of Nuvation Bio Inc. (NUVB), which transitioned to a commercial-stage company in 2025, trade around $5, approximately 49% below their 52-week high of $9.75 reached last December.
The company's lead product, IBTROZI, indicated for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer, received regulatory approval in China in January 2025, followed by U.S. FDA approval in June 2025 and approval in Japan in September 2025.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.